TBRG vs. CLRB, IMUX, RLMD, ASRT, COYA, FGEN, NOTV, LIFE, LIFW, and TELA
Should you be buying TruBridge stock or one of its competitors? The main competitors of TruBridge include Cellectar Biosciences (CLRB), Immunic (IMUX), Relmada Therapeutics (RLMD), Assertio (ASRT), Coya Therapeutics (COYA), FibroGen (FGEN), Inotiv (NOTV), aTyr Pharma (LIFE), MSP Recovery (LIFW), and TELA Bio (TELA). These companies are all part of the "medical" sector.
TruBridge (NASDAQ:TBRG) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations.
TruBridge has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.
Cellectar Biosciences has lower revenue, but higher earnings than TruBridge. TruBridge is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, TruBridge had 10 more articles in the media than Cellectar Biosciences. MarketBeat recorded 16 mentions for TruBridge and 6 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.46 beat TruBridge's score of 0.11 indicating that Cellectar Biosciences is being referred to more favorably in the news media.
TruBridge currently has a consensus price target of $18.50, indicating a potential upside of 110.95%. Cellectar Biosciences has a consensus price target of $20.00, indicating a potential upside of 551.47%. Given Cellectar Biosciences' higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than TruBridge.
Cellectar Biosciences has a net margin of 0.00% compared to TruBridge's net margin of -13.49%. TruBridge's return on equity of 10.33% beat Cellectar Biosciences' return on equity.
Cellectar Biosciences received 237 more outperform votes than TruBridge when rated by MarketBeat users. However, 100.00% of users gave TruBridge an outperform vote while only 56.07% of users gave Cellectar Biosciences an outperform vote.
88.6% of TruBridge shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 3.6% of TruBridge shares are held by company insiders. Comparatively, 4.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Cellectar Biosciences beats TruBridge on 9 of the 15 factors compared between the two stocks.
Get TruBridge News Delivered to You Automatically
Sign up to receive the latest news and ratings for TBRG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TBRG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TruBridge Competitors List
Related Companies and Tools
